Utility of functional imaging in prediction or assessment of treatment response and prognosis following thermotherapy

International Journal of Hyperthermia

Volumn 26, Issue 3, 2010, Pages 283-293

  Dewhirst, Mark W ^a   Thrall, Donald E ^b   Palmer, Gregory ^a   Schroeder, Thies ^a   Vujaskovic, Zeljko ^a   Charles, H Cecil ^a   MacFall, James ^a   Wong, Terence ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Functional imaging; Hyperthermia; MRI; Optical spectroscopy; PET; Prognosis

Indexed keywords

CARBON 11; COPPER 62; COPPER 64; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; OXYGEN 15;

BLOOD FLOW; CANCER CONTROL; CANCER RISK; CANCER STAGING; CELL PROLIFERATION; COST BENEFIT ANALYSIS; CYTOTOXICITY; ESOPHAGUS CANCER; HUMAN; HYPERTHERMIC THERAPY; MICROENVIRONMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SENSITIVITY AND SPECIFICITY; SOFT TISSUE SARCOMA; TREATMENT RESPONSE;

COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; HYPERTHERMIA, INDUCED; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MICROCIRCULATION; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; ROC CURVE; THERMOGRAPHY;

EID: 77951127855     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.3109/02656730903286214     Document Type: Review

References (54)

1. Garman KS, Nevins JR, Potti A. Genomic strategies for personalized cancer therapy. Hum Mol Genet 2007;16:R226-R232.
2. Swanton C, Szallasi Z, Brenton JD, Downward J. Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer. Breast Cancer Res 2008;10:214.
3. Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: A substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 2007;8:1071-1078.
4. Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM, Davidson NE, et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008;26:4063-4071.
5. Mendiratta P, Febbo PG. Genomic signatures associated with the development, progression, and outcome of prostate cancer. Mol Diagn Ther 2007;11:345-354.
6. Anguiano A, Nevins JR, Potti A. Toward the individualization of lung cancer therapy. Cancer 2008;113:S1760-S1767.
7. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, et al. Erlotinib in lung cancer - Molecular and clinical predictors of outcome. New England Journal of Medicine 2005; 353:133-144.
8. Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007;25:517-525.
9. Turnbull LW. Dynamic contrast-enhanced MRI in the diagnosis and management of breast cancer. NMR Biomed 2009;22:28-39.
10. Paldino MJ, Barboriak DP. Fundamentals of quantitative dynamic contrast-enhanced MR imaging. Magn Reson Imaging Clin N Am 2009;17:277-289.
11. Soares D, Law M. Magnetic resonance spectroscopy of the brain: Review of metabolites and clinical applications. Clin Radiol 2009;64:12-21.
12. Raghunand N. Tissue pH measurement by magnetic resonance spectroscopy and imaging. Methods Mol Med 2006;124:347-364.
13. Weber WA, Wieder H. Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging 2006;33:S27-S37.
14. Larson SM, Schoder H. New PET tracers for evaluation of solid tumor response to therapy. Q J Nucl Med Mol Imaging 2009;53:158-166.
15. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med 2008;49:S129-S148.
16. Padhani AR, Krohn KA, Lewis JS, Alber M. Imaging oxygenation of human tumours. Eur Radiol 2007;17:861-872.
17. Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4- methylthiosemicarbazone). J Nucl Med 2006;47:989-998.
18. Brown JQ, Wilke LG, Geradts J, Kennedy SA, Palmer GM, Ramanujam N. Quantitative optical spectroscopy: A robust tool for direct measurement of breast cancer vascular oxygenation and total hemoglobin content in vivo. Cancer Res 2009;69:2919-2926.
19. Tromberg BJ, Cerussi A, Shah N, Compton M, Durkin A, Hsiang D, Butler J, Mehta R. Imaging in breast cancer: Diffuse optics in breast cancer: Detecting tumors in premenopausal women and monitoring neoadjuvant chemotherapy. Breast Cancer Res 2005;7:279-285.
20. Brown JQ, Vishwanath K, Palmer GM, Ramanujam N. Advances in quantitative UV-visible spectroscopy for clinical and pre-clinical application in cancer. Curr Opin Biotechnol 2009;20:119-131.
21. Ohtsubo T, Saito H, Tanaka N, Kano E. Application of the ATP-bioluminescence assay to thermosensitivity testing for head and neck cancer. Eur Arch Oto-Rhino-Laryngol 1996;253:278-282.
22. Vaupel P, Okunieff P, Neuringer LJ. In Vivo P-31-NMR spectroscopy of muring tumors before and after localized hyperthermia. Int J Hyperthermia 1990;6:15-31.
23. Sijens PE, Bovee W, Seijkens D, Koole P, Los G, Vanrijssel RH. Murine mammary tumor response to hyperthermia and radiotherapy evaluated by in vivo P-31 nuclear magnetic resonance spectroscopy. Cancer Research 1987;47: 6467-6473.
24. Prescott DM, Charles HC, Sostman HD, Dodge RK, Thrall DE, Page RL, Tucker JA, Harrelson JM, Leopold KA, Oleson JR, et al. Therapy monotiring in human and canine soft-tissue sarcomas using magnetic resonance imaging and spectroscopy. International Journal of Radiation Oncology Biology Physics 1994;28:415-423.
25. Baur A, Stabler A, Wendtner CM, Arbogast S, Rahman SA, Santl M, Issels R, Reiser M. MR-imaging changes of musculoskeletal soft-tissue sarcomas associated with neoadjuvant chemotherapy and hyperthermia. Int J Hyperthermia 2003;19:391-401.
26. Craciunescu O, Blackwell K, Jones EL, MacFall J, Yu D, Vujaskovic Z, Wong TZ, Liotcheva VB, Rosen E, Prosnitz L, et al. DCE-MRI Parameters Have Potential to Predict Response of Locally Advanced Breast Cancer Patients to Neoadjuvant Chemotherapy and Hyperthermia: A Pilot Study [Response]. Int J Hyperthermia 2009;25(6):405-415.
27. Jones DN, Brizel DM, Charles HC, Dewhirst MW, Friedman HS, McCowage G, et al. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcomas using fluorine-18-FDG PET. J Nucl Med. 1996 May;37(9):P38.
28. Jones DN, McCowage GB, Sostman HD, Brizel DM, Layfield L, Charles HC, Dewhirst MW, Prescott DM, Friedman HS, Harrelson JM, et al. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J Nucl Med 1996;37:1438-1444.
29. Westerterp M, Omloo JM, Sloof GW, Hulshof MC, Hoekstra OS, Crezee H, Boellaard R, Vervenne WL, Kate ten, van Lanschot FJ, JJ. Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET. Int J Hyperthermia 2006;22:149-160.
30. Amthauer H, Denecke T, Rau B, Hildebrandt B, Hunerbein M, Ruf J, Schneider U, Gutberlet M, Schlag PM, Felix R, et al. Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: Correlation with endorectal ultrasound and histopathology. Eur J Nucl Med Mol Imaging 2004;31:811-819.
31. Gooley T, Leisenring W, Crowley J, Storer B. Estimation of failure probabilities in the presence of competing risks: New representations of the old estimators. Statist Med. 1999; 18:695-706.
32. Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, Machulla HJ, Bares R. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005;46:253-260.
33. Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, Peters LJ. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006;24:2098-2104.
34. Lee N, Nehmeh S, Schoder H, Fury M, Chan K, Ling CC, Humm J. Prospective Trial Incorporating Pre-/Mid- Treatment [(18)F]-Misonidazole Positron Emission Tomography for Head-and-Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009;75(1):101-108.
35. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, Dewhirst MW. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56:941-943.
36. Thrall DE, Larue SM, Pruitt AF, Case B, Dewhirst MW. Changes in tumour oxygenation during fractionated hyperthermia and radiation therapy in spontaneous canine sarcomas. Int J Hyperthermia. 2006 Aug;22:365-373.
37. Lora-Michiels M, Yu D, Sanders L, Poulson JM, Azuma C, Case B, Vujaskovic Z, Thrall DE, Charles HC, Dewhirst MW. Extracellular pH and P-31 magnetic resonance spectroscopic variables are related to outcome in canine soft tissue sarcomas treated with thermoradiotherapy. Clin Cancer Res 2006;12:5733-5740.
38. Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW, Mueller-Klieser W. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;51:349-353.
39. Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfor K, Rofstad EK, Mueller-Klieser W. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Research 2000;60:916-921.
40. Walenta S, Chau TV, Schroeder T, Lehr HA, Kunz- Schughart LA, Fuerst A, et al. Metabolic classification of human rectal adenocarcinomas: A novel guideline for clinical oncologists? J Cancer Res Clin Oncol. 2003 Jun;129:321-326.
41. Schneiderhan W, Scheler M, Holzmann K, Marx M, Gschwend J, Buchholz M, Gress T, Adler G, Seufferlein T, Oswald F. CD147 sliencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in invivo and in-vitro models. Gut 2009;58(10):1391-1398.
42. Hashimoto T, Hussien R, Oommen S, Gohil K, Brooks GA. Lactate sensitive transcription factor network in L6 cells: Activation of MCT1 and mitochondrial biogenesis. FASEB J. 2007 Aug;21:2602-2612.
43. Ishibashi Y, Matsumoto T, Niwa M, Suzuki Y, Omura N, Hanyu N, Nakada K, Yanaga K, Yamada K, Ohkawa K, et al. CD147 and matrix metalloproteinase-2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma. Cancer 2004;101:1994-2000.
44. Tarnawski R, Sokol M, Pieniazek P, Maciejewski B, Walecki J, Miszczyk L, Krupska T, H-1-MRS in vivo predicts the early treatment outcome of postoperative radiotherapy for malignant gliomas. International Journal of Radiation Oncology Biology Physics. 2002 Apr;52:1271-1276.
45. Yokota H, Guo JF, Matoba M, Higashi K, Tonami H, Nagao Y. Lactate, choline, and creatine levels measured by vitro H-1- MRS as prognostic parameters in patients with non-small-cell lung cancer. Journal of Magnetic Resonance Imaging 2007;25:992-999.
46. Viglianti BL, Lora-Michiels M, Poulson JM, Lan L, Yu D, Sanders L, Craciunescu O, Vujaskovic Z, Thrall DE, Macfall J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a predictor of clinical outcome in canine spontaneous soft tissue sarcomas treated with thermoradiotherapy. Clin Cancer Res 2009;15:4993-5001.
47. Dewhirst MW, Poulson JM, Yu D, Sanders L, Lora-Michiels M, Vujaskovic Z, Jones EL, Samulski TV, Powers BE, Brizel DM, et al. Relation between pO2, 31P magnetic resonance spectroscopy parameters and treatment outcome in patients with high-grade soft tissue sarcomas treated with thermoradiotherapy. Int J Radiat Oncol Biol Phys 2005;61:480-491.
48. Liotta LA, Mandler R, Murano G, Katz DA, Gordon RK, Chiang PK, Schiffmann E. Tumor cell autocrine motility factor. Proc Natl Acad Sci U S A 1986;83:3302-3306.
49. Kukreti S, Cerussi A, Tromberg B, Gratton E. Intrinsic nearinfrared spectroscopic markers of breast tumors. Dis Markers. 2008;25:281-290.
50. Zhou C, Choe R, Shah N, Durduran T, Yu G, Durkin A, Hsiang D, Mehta R, Butler J, Cerussi A, et al. Diffuse optical monitoring of blood flow and oxygenation in human breast cancer during early stages of neoadjuvant chemotherapy. J Biomed Opt 2007;12:051903-1-051903-51911
51. Palmer GM, Viola RJ, Schroeder T, Yarmolenko PS, Dewhirst MW, Ramanujam N. Quantitative diffuse reflectance and fluorescence spectroscopy: Tool to monitor tumor physiology in vivo. J Biomed Opt 2009;14:024010-1-024010-24018
52. Vishwanath K, Yuan H, Barry WT, Dewhirst MW, Ramanujam N. Using Optical Spectroscopy to Longitudinally Monitor Physiological Changes within Solid Tumors. Neoplasia. 2009;11(9):889-900.
53. Bartel TB, Haessler J, Brown TL, Shaughnessy Jr. JD, van Rhee F, Anaissie E, Alpe T, Angtuaco E, Walker R, Epstein J, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 2009;114: 2068-2076.
54. Tzika AA, Astrakas L, Cao HH, Mintzopoulos D, Andronesi OC, Mindrinos M, Zhang JW, Rahme LG, Blekas KD, Likas AC, et al. Combination of high-resolution magic angle spinning proton magnetic resonance spectroscopy and microscale genomics to type brain tumor biopsies. International Journal of Molecular Medicine 2007;20:199-208.